Philippines Pharmaceuticals & Healthcare Report Q2 2015 - New Market Study Published

20.04.2015 04:41:41 - Fast Market Research recommends "Philippines Pharmaceuticals & Healthcare Report Q2 2015" from Business Monitor International, now available (live-PR.com) - Our outlook for the Philippines' pharmaceutical sector remains bullish, driven by an increasing population and high burden of disease profile. Generic medicines will continue to account for an increasing share of pharmaceutical sales in the Philippines, galvanised by expanding government provision of healthcare as well as improvements in generic drug distribution. This provides strong growth opportunities for generic drug manufacturers in an emerging market where economic growth will be sustained by robust private consumption. Howeve r, current access to medicines and treatment will continue to negatively impact the wider market. Full Report Details at - www.fastmr.com/prod/965820_philippines_pharmaceu .. Headline Expenditure Projections * Pharmaceuticals: PHP140.20bn (USD3.25bn) in 2013, rising to PHP145.05bn (USD3.26bn) in 2014; +3.5% in local currency terms and +0.4% in US dollar terms. * Healthcare: PHP545.09bn (USD12.62bn) in 2013, rising to PHP612.04bn (USD13.75bn) in 2014; +12.3% in local currency terms and +9.0% in US dollar terms. Risk/Reward Index : Out of the 19 pharmaceutical markets assessed in Asia Pacific, the Philippines remain in 14th place (scoring 45.3 out of 100), trailing the regional average in most metrics. In Q115, Japan is ranked as the most attractive market in the Asia Pacific region (scoring 78.1 out of 100), followed by South Korea (68.6). Compared with its peers, the Philippines' RRI score is dragged down by industry characteristics such as policy enforcement. Key Trends And Developments November * Healthcare problems, such as accessibility, availability and affordability, will persist nationwide beyond 2015 even if the Philippines achieves its health-related Millennium Development Goal (MDG) commitments by 2015, according to state-owned Philippine Institute for Development Studies (PIDS). According to PIDS Senior Research Fellow Celia Reyes, this is because Filipinos living in Luzon still receive better access to health services and facilities than Filipinos in the Visayas and Mindanao.... The Philippines Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments. BMI's Philippines Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Philippines pharmaceutical and healthcare industry. Key Benefits * Benchmark BMI's pharmaceutical and healthcare market forecasts for Philippines, to test other views - a key input for successful budgeting and strategic business planning in the Philippine pharmaceutical and healthcare market. * Target business opportunities and risks in the Philippine pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Philippines. * Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables. Coverage BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMIs forecast analysis, and taken together with BMIs political, economic and business environment SWOTs, it gives a complete overview of market climate. BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts: * Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per 000 population). * Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD). * Patented Drug Market: Prescription drug sales (USDbn & % of total sales). Browse our complete collection of Healthcare research reports at www.fastmr.com/catalog/browse.aspx?category=15 About Fast Market Research Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.